Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more
Imugene Limited (IUGNF) - Net Assets
Latest net assets as of June 2025: $45.03 Million USD
Based on the latest financial reports, Imugene Limited (IUGNF) has net assets worth $45.03 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($83.59 Million) and total liabilities ($38.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $45.03 Million |
| % of Total Assets | 53.87% |
| Annual Growth Rate | 7.04% |
| 5-Year Change | -30.74% |
| 10-Year Change | 473.18% |
| Growth Volatility | 161.02 |
Imugene Limited - Net Assets Trend (1993–2025)
This chart illustrates how Imugene Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Imugene Limited (1993–2025)
The table below shows the annual net assets of Imugene Limited from 1993 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $45.03 Million | -61.92% |
| 2024-06-30 | $118.25 Million | -37.64% |
| 2023-06-30 | $189.63 Million | +36.71% |
| 2022-06-30 | $138.70 Million | +113.33% |
| 2021-06-30 | $65.02 Million | +8.71% |
| 2020-06-30 | $59.81 Million | +119.11% |
| 2019-06-30 | $27.29 Million | +76.37% |
| 2018-06-30 | $15.48 Million | +35.81% |
| 2017-06-30 | $11.39 Million | +45.03% |
| 2016-06-30 | $7.86 Million | +1.61% |
| 2015-06-30 | $7.73 Million | +14.85% |
| 2014-06-30 | $6.73 Million | +256.87% |
| 2013-06-30 | $1.89 Million | +75.74% |
| 2012-06-30 | $1.07 Million | -74.48% |
| 2011-06-30 | $4.21 Million | +10.96% |
| 2010-06-30 | $3.79 Million | -28.82% |
| 2009-06-30 | $5.33 Million | +14.05% |
| 2008-06-30 | $4.67 Million | -0.63% |
| 2007-06-30 | $4.70 Million | -27.27% |
| 2006-06-30 | $6.46 Million | -25.31% |
| 2005-06-30 | $8.65 Million | +59.30% |
| 2004-06-30 | $5.43 Million | -27.03% |
| 2003-06-30 | $7.44 Million | +838.83% |
| 2002-06-30 | $792.83K | +449.97% |
| 2001-06-30 | $-226.54K | -108.15% |
| 2000-06-30 | $2.78 Million | -53.65% |
| 1999-06-30 | $6.00 Million | -11.25% |
| 1998-06-30 | $6.75 Million | -9.35% |
| 1997-06-30 | $7.45 Million | -8.25% |
| 1996-06-30 | $8.12 Million | -23.53% |
| 1995-06-30 | $10.62 Million | -5.05% |
| 1994-06-30 | $11.19 Million | +118.86% |
| 1993-06-30 | $5.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Imugene Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35029661900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $380.68 Million | 845.35% |
| Other Comprehensive Income | $17.08 Million | 37.92% |
| Total Equity | $45.03 Million | 100.00% |
Imugene Limited Competitors by Market Cap
The table below lists competitors of Imugene Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Union Dental Holdings Inc
OTCQB:XCRT
|
$4.78 Million |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
$4.78 Million |
|
Arkle Resources PLC
STU:48O
|
$4.79 Million |
|
Thunder Bridge Capital Partners IV Inc. Warrant
NASDAQ:THCPW
|
$4.79 Million |
|
Terrain Minerals Ltd
AU:TMX
|
$4.78 Million |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
$4.78 Million |
|
Plaza Centers NV
WAR:PLZ
|
$4.78 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
$4.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Imugene Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 118,254,407 to 45,032,333, a change of -73,222,074 (-61.9%).
- Net loss of 69,021,612 reduced equity.
- Share repurchases of 1,320,000 reduced equity.
- New share issuances of 1,579 increased equity.
- Other comprehensive income decreased equity by 20,695,326.
- Other factors increased equity by 17,813,285.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.02 Million | -153.27% |
| Share Repurchases | $1.32 Million | -2.93% |
| Share Issuances | $1.58K | +0.0% |
| Other Comprehensive Income | $-20.70 Million | -45.96% |
| Other Changes | $17.81 Million | +39.56% |
| Total Change | $- | -61.92% |
Book Value vs Market Value Analysis
This analysis compares Imugene Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-06-30 | $17.50 | $0.02 | x |
| 1994-06-30 | $10.63 | $0.02 | x |
| 1995-06-30 | $7.61 | $0.02 | x |
| 1996-06-30 | $5.59 | $0.02 | x |
| 1997-06-30 | $4.54 | $0.02 | x |
| 1998-06-30 | $3.85 | $0.02 | x |
| 1999-06-30 | $2.76 | $0.02 | x |
| 2000-06-30 | $1.16 | $0.02 | x |
| 2001-06-30 | $-0.09 | $0.02 | x |
| 2002-06-30 | $0.06 | $0.02 | x |
| 2003-06-30 | $0.10 | $0.02 | x |
| 2004-06-30 | $0.05 | $0.02 | x |
| 2005-06-30 | $2.43 | $0.02 | x |
| 2006-06-30 | $1.67 | $0.02 | x |
| 2007-06-30 | $1.21 | $0.02 | x |
| 2008-06-30 | $1.15 | $0.02 | x |
| 2009-06-30 | $1.19 | $0.02 | x |
| 2010-06-30 | $0.89 | $0.02 | x |
| 2011-06-30 | $0.99 | $0.02 | x |
| 2012-06-30 | $0.25 | $0.02 | x |
| 2013-06-30 | $0.20 | $0.02 | x |
| 2014-06-30 | $0.33 | $0.02 | x |
| 2015-06-30 | $0.22 | $0.02 | x |
| 2016-06-30 | $0.20 | $0.02 | x |
| 2017-06-30 | $0.19 | $0.02 | x |
| 2018-06-30 | $0.20 | $0.02 | x |
| 2019-06-30 | $0.26 | $0.02 | x |
| 2020-06-30 | $0.50 | $0.02 | x |
| 2021-06-30 | $0.47 | $0.02 | x |
| 2022-06-30 | $0.84 | $0.02 | x |
| 2023-06-30 | $1.03 | $0.02 | x |
| 2024-06-30 | $0.57 | $0.02 | x |
| 2025-06-30 | $0.21 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Imugene Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -153.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1569.81%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.86x
- Recent ROE (-153.27%) is below the historical average (-49.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 4.75% | 0.00% | 0.00x | 1.11x | $-268.10K |
| 1994 | -7.82% | 0.00% | 0.00x | 1.01x | $-1.99 Million |
| 1995 | -20.10% | -1135.64% | 0.02x | 1.12x | $-3.20 Million |
| 1996 | -52.25% | -1526.62% | 0.03x | 1.14x | $-5.06 Million |
| 1997 | -29.28% | -56.54% | 0.44x | 1.17x | $-2.93 Million |
| 1998 | -67.30% | 0.00% | 0.00x | 1.17x | $-5.22 Million |
| 1999 | -82.24% | 0.00% | 0.00x | 1.15x | $-5.53 Million |
| 2000 | -159.02% | 0.00% | 0.00x | 1.32x | $-4.70 Million |
| 2001 | 0.00% | -3537.32% | 0.05x | 0.00x | $-4.02 Million |
| 2002 | -98.63% | -60.53% | 1.53x | 1.07x | $-861.28K |
| 2003 | 9.39% | 3679263.16% | 0.00x | 1.09x | $-45.27K |
| 2004 | -38.96% | 0.00% | 0.00x | 1.11x | $-2.66 Million |
| 2005 | -20.73% | 0.00% | 0.00x | 1.05x | $-2.66 Million |
| 2006 | -33.84% | 0.00% | 0.00x | 1.12x | $-2.83 Million |
| 2007 | -49.02% | -146564.89% | 0.00x | 1.12x | $-2.77 Million |
| 2008 | -40.92% | 0.00% | 0.00x | 1.11x | $-2.38 Million |
| 2009 | 12.21% | 0.00% | 0.00x | 1.08x | $117.65K |
| 2010 | -40.49% | 0.00% | 0.00x | 1.08x | $-1.91 Million |
| 2011 | 9.88% | 18.66% | 0.48x | 1.11x | $-5.15K |
| 2012 | -291.87% | -1328.04% | 0.18x | 1.23x | $-3.24 Million |
| 2013 | -82.69% | -752.82% | 0.08x | 1.37x | $-1.75 Million |
| 2014 | -31.43% | -393.07% | 0.06x | 1.28x | $-2.79 Million |
| 2015 | -31.57% | -382.16% | 0.07x | 1.18x | $-3.21 Million |
| 2016 | -34.76% | -174.62% | 0.16x | 1.21x | $-3.52 Million |
| 2017 | -22.00% | -215.38% | 0.09x | 1.11x | $-3.65 Million |
| 2018 | -25.42% | -213.69% | 0.11x | 1.09x | $-5.48 Million |
| 2019 | -28.49% | -188.39% | 0.13x | 1.13x | $-10.50 Million |
| 2020 | -17.57% | -254.18% | 0.06x | 1.09x | $-16.49 Million |
| 2021 | -28.38% | -255.19% | 0.10x | 1.10x | $-24.96 Million |
| 2022 | -27.30% | -291.97% | 0.09x | 1.06x | $-51.74 Million |
| 2023 | -19.99% | -321.91% | 0.06x | 1.04x | $-56.88 Million |
| 2024 | -126.58% | -3011.67% | 0.03x | 1.28x | $-161.51 Million |
| 2025 | -153.27% | -1569.81% | 0.05x | 1.86x | $-73.52 Million |
Industry Comparison
This section compares Imugene Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Imugene Limited (IUGNF) | $45.03 Million | 4.75% | 0.86x | $4.78 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |